

University of Dundee

Author Correction

Bartolome, Fernando; Esteras, Noemi; Martin-Requero, Angeles; Boutoleau-Bretonniere, Claire; Vercelletto, Martine; Gabelle, Audrey

Published in:
Scientific Reports

DOI:
[10.1038/s41598-018-22152-9](https://doi.org/10.1038/s41598-018-22152-9)

Publication date:
2018

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Bartolome, F., Esteras, N., Martin-Requero, A., Boutoleau-Bretonniere, C., Vercelletto, M., Gabelle, A., Ber, I. L., Honda, T., Dinkova-Kostova, A. T., Hardy, J., Carro, E., & Abramov, A. Y. (2018). Author Correction: Pathogenic p62/SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates (Scientific Reports DOI: 10.1038/s41598-017-01678-4). *Scientific Reports*, 8, 1-2. Article 4064. <https://doi.org/10.1038/s41598-018-22152-9>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

SCIENTIFIC REPORTS



OPEN

Author Correction: Pathogenic *p62/SQSTM1* mutations impair energy metabolism through limitation of mitochondrial substrates

Fernando Bartolome^{1,2,3}, Noemi Esteras³, Angeles Martin-Requero^{4,5}, Claire Boutoleau-Bretonniere^{6,7,8}, Martine Vercelletto^{7,8}, Audrey Gabelle⁹, Isabelle Le Ber^{10,11}, Tadashi Honda¹², Albena T. Dinkova-Kostova¹³, John Hardy^{3,14}, Eva Carro^{1,2} & Andrey Y. Abramov³

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-017-01678-4>, published online 10 May 2017

The Acknowledgements section in this Article is incomplete.

“We are grateful to the patients and donors without which these work would not have been possible. We thank Patricio Aller and Elena de Blas in the assessment of GSH levels. We also thank the i+12 Proteomic Unit, in particular Ines Garcia-Consuegra for her advice in the Complex I activity measurement in fibroblasts. We also thank Maria Teresa Seiseddos from the CIB Microscopy Unit helping to setup the fluorescence measurements in living cells. FB is supported by a Sara Borrell fellowship from the Spanish *Instituto de Salud Carlos III*. N.E. holds a postdoctoral fellowship from the Spanish *Fundación Alfonso Martín Escudero*. This work was supported by a career development award from the MRC (G0700183), by an ALS Association Initiated award (ID#2109) by the Motor Neuron Disease Association, partially by the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson’s Disease Consortium (UKPDC) whose members are from the UCL/Institute of Neurology, the University of Sheffield and the MRC Protein Phosphorylation Unit at the University of Dundee and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. AMR is supported by grant CTQ2015-66313-R from MINECO, Spain. ILB has received funding from the program “Investissements d’avenir” ANR-10-IAIHU-06, FP7-Neuromics, PHRC FTLD-exomes. EC is supported by grants from the *Instituto de Salud Carlos III* (FIS2012/00486; BA14/00058), FEDER, *Fundación Investigación Médica Mutua Madrileña* (2010/0004), *Fundación Ramón Areces* (CIVP16A1825), and *CIBERNED*”

should read:

“We are grateful to the patients and donors without which these work would not have been possible. We thank Patricio Aller and Elena de Blas in the assessment of GSH levels. We also thank the i+12 Proteomic Unit, in particular Ines Garcia-Consuegra for her advice in the Complex I activity measurement in fibroblasts. We also thank Maria Teresa Seiseddos from the CIB Microscopy Unit helping to setup the fluorescence measurements in

¹Neurodegenerative Disorders group, Instituto de Investigación Hospital 12 de Octubre (i+12), Av Córdoba, Madrid, 28041, Spain. ²Biomedical Research Networking Centre on Neurodegenerative Diseases (CIBERNED), Madrid, Spain. ³Department of Molecular Neuroscience, UCL Institute of Neurology Queen Square, London, WC1N 3BG, UK. ⁴Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (CSIC), Ramiro de Maeztu 9, Madrid, 28040, Spain. ⁵Biomedical Research Networking Centre on Rare Diseases (CIBERER), Madrid, Spain. ⁶Laboratoire d’études des mécanismes cognitifs, EA 3082, Université Lyon 2, Bron, F-69500, France. ⁷CHU Nantes, Centre de Mémoire et de Ressource et Recherche (CM2R), Nantes, France. ⁸Inserm, CIC 04, Nantes, France. ⁹Memory Research and Resources Center, Department of Neurology, Montpellier University Hospital, Montpellier, France. ¹⁰CNR-MAJ, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France. ¹¹ICM, Inserm U1127, CNRS UMR 7225, Sorbonne Universités, UPMC-P6 UMR S 1127 - Hôpital Pitié-Salpêtrière, Paris, France. ¹²Department of Chemistry and Institute of Chemical Biology & Drug Discovery Stony Brook University Stony Brook, New York, 11794, USA. ¹³Division of Cancer Research, School of Medicine University of Dundee, Dundee, DD1 9SY, UK. ¹⁴Reta Lilla Weston Laboratories, London, WC1N 3BG, UK. Correspondence and requests for materials should be addressed to F.B. (email: fbartolome.imas12@h12o.es) or A.Y.A. (email: a.abramov@ucl.ac.uk)

living cells. FB is supported by a *Sara Borrell* fellowship from the Spanish *Instituto de Salud Carlos III*. N.E. holds a postdoctoral fellowship from the Spanish *Fundación Alfonso Martín Escudero*. This work was supported by a career development award from the MRC (G0700183), by an ALS Association Initiated award (ID#2109) by the Motor Neuron Disease Association, partially by the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson's Disease Consortium (UKPDC) whose members are from the UCL/Institute of Neurology, the University of Sheffield and the MRC Protein Phosphorylation Unit at the University of Dundee and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. AMR is supported by grant CTQ2015-66313-R from MINECO, Spain. ILB has received funding from the program "Investissements d'avenir" ANR-10-LAIHU-06, FP7-Neuromics, PHRC FTLD-exomes. EC is supported by grants from the *Instituto de Salud Carlos III* (FIS2012/00486; BA14/00058), FEDER, *Fundación Investigación Médica Mutua Madrileña* (2010/0004), *Fundación Ramón Areces* (CIVP16A1825), and *CIBERNED*. Thanks to Reata Pharmaceuticals for their support and for providing us the RTA-408 activator."



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018